Marinus Pharmaceuticals Adds $21M Series C
07 January 2013
Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.
CoDa Therapeutics Completes $49 Million Fund Raising
24 July 2012
CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.
Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.
06 October 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.
Marinus Pharmaceuticals Issued Patent for Ganaxolone
29 April 2011
Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.
CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.
18 April 2011
San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.
17 April 2011
Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.
30 June 2022
A project on remote sale of prescription drugs has been presented
30 June 2022
New microencapsulation approach allows slow release of peptide drugs
29 June 2022
Heparin affinity chromatography promising for extracellular vesicle purification
29 June 2022